Biofrontera (NASDAQ:BFRI – Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 13th. Analysts expect Biofrontera to post earnings of ($0.07) per share and revenue of $14.53 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Biofrontera Price Performance
Biofrontera stock opened at $0.88 on Tuesday. The company’s 50-day moving average is $1.07 and its 200-day moving average is $1.04. The firm has a market capitalization of $6.82 million, a PE ratio of -0.39 and a beta of 0.30. Biofrontera has a fifty-two week low of $0.65 and a fifty-two week high of $2.43.
Wall Street Analysts Forecast Growth
Separately, Benchmark reissued a “buy” rating and set a $7.00 price target on shares of Biofrontera in a research report on Friday, November 15th.
About Biofrontera
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
Featured Stories
- Five stocks we like better than Biofrontera
- Want to Profit on the Downtrend? Downtrends, Explained.
- How to Protect Your Portfolio When Inflation Is Rising
- Most active stocks: Dollar volume vs share volume
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
